ASH: Iron Deficiency More Likely in Formula-Fed Preemies
More infants in formula-fed versus breastfed group developed iron deficiency, despite having higher mean total daily iron intake.
Diagnosis & Disease Information
Odronextamab Appears Safe, Effective in Relapsed/Refractory Follicular Lymphoma
Odronextamab has demonstrated safety and efficacy in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Frontline Regimens for MM Are Similar Across the World; Later Lines of Treatment Vary
Worldwide, bortezomib-based triplets are the most common frontline treatment for multiple myeloma, but regimens used in later lines vary.
PTCy Plus Tacrolimus and MMF “Should Be Standard” GVHD Prophylaxis in RIC PBSCT
PTCy plus tacrolimus and MMF should be standard GVHD prophylaxis in adults who receive a well-matched PBSCT after RIC, according to researchers.
Long-Term Risk of ITP Higher in Patients With Persistent, Isolated Mild Thrombocytopenia
Researchers sought to assess the risk of progression to ITP or hematologic neoplasia in adults with persistent, isolated mild thrombocytopenia.
Genomic Biomarker and Socioenvironmental Experiences Linked in Transplant Recipients
Researchers sought to determine whether there was a link between socioenvironmental experiences and a particular immunoregulatory pattern in recipients of HCT.
Silent Cerebral Infarction May Be Common on MRI in Patients With Immune Thrombotic Thrombocytopenic Purpura
Researchers sought to determine whether MRI could show evidence of brain infarction in patients with iTTP.
Low-Dose Lenalidomide Confirmed to Reduce Time to Transfusion Dependence in Lower-Risk MDS
Researchers sought to determine whether low-dose lenalidomide would prolong time to transfusion dependence among patients with low-risk MDS.
Zanubrutinib Outperforms Ibrutinib in Relapsed/Refractory CLL/SLL
Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.
- Loading...
Loading...
Loading... 
Loading...